Organigram Global (OGI) vs. Its Competitors Head-To-Head Survey

Organigram Global (NASDAQ:OGI) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its peers? We will compare Organigram Global to similar businesses based on the strength of its risk, profitability, earnings, valuation, dividends, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

34.6% of Organigram Global shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 0.1% of Organigram Global shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Organigram Global has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Organigram Global’s peers have a beta of 2.56, indicating that their average stock price is 156% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Organigram Global and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	0	1	2	0	2.67
Organigram Global Competitors	4257	10483	18211	824	2.46

As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 23.28%. Given Organigram Global’s peers higher probable upside, analysts plainly believe Organigram Global has less favorable growth aspects than its peers.

Profitability

This table compares Organigram Global and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organigram Global	28.14%	-13.39%	-8.67%
Organigram Global Competitors	-278.23%	-150.06%	-21.87%

Valuation and Earnings

This table compares Organigram Global and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Organigram Global	$185.07 million	-$17.70 million	2.10
Organigram Global Competitors	$1.89 billion	$138.79 million	10.83

Organigram Global’s peers have higher revenue and earnings than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Organigram Global peers beat Organigram Global on 8 of the 13 factors compared.

Organigram Global Company Profile

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.